Renee Reynolds a clinical trials coordinator for the Hunter New England Local Health District located north of Sydney, and colleagues including Kristine Macartney at the National Centre for Immunization Research and Surveillance, Australia execute a study describing the short-term safety profile of priming doses of the Spikevax (Moderna) and Nuvaxovid (Novavax) vaccines administered September 2021 and September 2023. Working with Australia’s active vaccine safety surveillance system known as AusVaxSafety, the researchers sent online surveys three and eight days post-vaccination. Sending a total of 131,775 day 3 surveys, the response rate equaled 38.5% (N=50,721). The team of researchers sent 43,785 day 8 surveys matched with day 3 survey responses and an ensuing response rate of 71.5% (N=31,355). A notably high percentage (50.7%) of respondents reported any adverse event following immunization (AEFI) in the 0–3 days after vaccination and 24.6% reported any AEFI 4–7 days after vaccination. Overall, the authors conclude the major COVID-19 vaccines have an overall safe profile. However, study data reveals that on average, 3.1% of respondents needed medical review after receiving either Moderna or Novavax After the second jab of Moderna’s mRNA Spikevax 4.8% of the respondents needed to seek medical intervention. What percentage of respondents needed to go see a physician or provider, classified as a medical review?